NCT01222286Phase 2Completed

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

Study sponsor: Innate Pharma

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2012-07Actual
Enrollment · participants30Actual
Source updated2026-05-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.